Reference trademark issue [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2018-07-24 11:05 (2544 d 16:01 ago) – Posting: # 19087
Views: 3,353

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Regards'
Kakarla

Complete thread:

UA Flag
Activity
 Admin contact
23,434 posts in 4,931 threads, 1,674 registered users;
49 visitors (0 registered, 49 guests [including 18 identified bots]).
Forum time: 03:07 CEST (Europe/Vienna)

For every expert there is an equal and opposite expert.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5